stoxline Quote Chart Rank Option Currency Glossary
  
Vaccinex, Inc. (VCNX)
7.5  0 (0%)    03-28 11:11
Open: 8.11
High: 8.11
Volume: 10,021
  
Pre. Close: 7.5
Low: 7.5
Market Cap: 9(M)
Technical analysis
2024-03-28 11:20:41 AM
Short term     
Mid term     
Targets 6-month :  10.06 1-year :  10.9
Resists First :  8.61 Second :  9.34
Pivot price 8.11
Supports First :  7.44 Second :  6.19
MAs MA(5) :  7.66 MA(20) :  8.12
MA(100) :  9.42 MA(250) :  38.87
MACD MACD :  -0.4 Signal :  -0.3
%K %D K(14,3) :  4.4 D(3) :  4.4
RSI RSI(14): 42.8
52-week High :  100.8 Low :  7.13
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ VCNX ] has closed above bottom band by 21.6%. Bollinger Bands are 56% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 7.65 - 7.72 7.72 - 7.77
Low: 7.29 - 7.39 7.39 - 7.45
Close: 7.34 - 7.5 7.5 - 7.59
Company Description

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.

Headline News

Thu, 28 Mar 2024
Short Interest in Vaccinex, Inc. (NASDAQ:VCNX) Declines By 40.5% - Defense World

Wed, 27 Mar 2024
Vaccinex to raise $1.5M through in a direct offering (NASDAQ:VCNX) - Seeking Alpha

Wed, 27 Mar 2024
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private ... - The Bakersfield Californian

Wed, 27 Mar 2024
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the ... - GlobeNewswire

Wed, 21 Feb 2024
Vaccinex Inc Broadens Reach with ActivMab® Technology Deals - TipRanks.com - TipRanks

Thu, 15 Feb 2024
Vaccinex, Inc. Announces Reverse Stock Split - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out -11 (M)
Shares Float 0 (M)
Held by Insiders 1.17e+006 (%)
Held by Institutions 326310 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 0
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -83.87
Profit Margin 0 %
Operating Margin -29 %
Return on Assets (ttm) 170 %
Return on Equity (ttm) -257.6 %
Qtrly Rev. Growth 797.6 %
Gross Profit (p.s.) 0
Sales Per Share -364.54
EBITDA (p.s.) -1.20175e+007
Qtrly Earnings Growth -2.288e+007 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value -0.1
Price to Sales -0.03
Price to Cash Flow 0
Stock Dividends
Dividend 14830
Forward Dividend 1960
Dividend Yield 192597%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android